How well does Cotellic(Cobimetinib) work?

Cobimetinib demonstrates significant clinical benefits in BRAF-mutant melanoma and histiocytic neoplasms.

Clinical Outcomes in Target Populations

In melanoma (Trial 1), cobimetinib + vemurafenib improved median progression-free survival (12.3 vs. 7.2 months; HR 0.56) and overall survival (22.3 vs. 17.4 months; HR 0.69) versus vemurafenib alone. Objective response rate (ORR) was 70% (16% complete responses). For histiocytic neoplasms (Trial 2), cobimetinib monotherapy achieved a 76.9% PET-based ORR (61.5% complete responses) and 46.2% RECIST-based ORR. Efficacy was observed across BRAF V600E/K and wild-type subtypes. Median duration of response exceeded 13 months in melanoma and 31 months in histiocytosis. Subgroup analyses supported consistent benefits in BRAF mutation variants.

Related Columns

Cobimetinib(Cotellic)

Cotellic is indicated for the treatment of adult patients with melanoma...

WeChat Scan
Free Inquiry

How effective is cobimetinib in treatment?

Cobimetinib is an oral anticancer drug belonging to the class of MEK inhibitors. It mainly works by inhibiting the activity of MEK to stop or slow down the growth of cancer cells, thereby prolonging t...

How is the therapeutic effect of cobimetinib?

Cobimetinib is suitable for the treatment of unresectable or metastatic melanoma with BRAFV600E or V600K mutations in combination with vemurafenib, as well as adult patients with histiocytes treated w...